Tremfya (guselkumab) works by blocking a specific immune signal called interleukin-23, or IL-23, that drives inflammation in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease. Unlike older biologics that suppress broader parts of the immune system, Tremfya targets just one piece of the inflammatory chain, which helps explain both its effectiveness and its relatively mild side effect profile.
The Inflammatory Chain Tremfya Interrupts
To understand what Tremfya does, it helps to know what goes wrong in these conditions. In psoriasis, for example, immune cells in the skin called dendritic cells overproduce IL-23. That excess IL-23 acts like a survival signal for a type of immune cell called a Th17 cell. When Th17 cells receive this signal, they multiply and pump out their own inflammatory molecules, particularly IL-17A and IL-22.
Those downstream molecules do real, visible damage. IL-17A recruits white blood cells to the skin, promotes new blood vessel growth, and activates skin cells to release even more inflammatory signals. IL-22 causes skin cells to reproduce too fast, which is what creates the thick, scaly plaques characteristic of psoriasis. Together, these molecules create a self-reinforcing loop of inflammation and skin overgrowth.
Tremfya binds specifically to the p19 subunit of IL-23, preventing it from ever reaching the Th17 cells. Without that survival signal, Th17 cells die off and stop producing the molecules that cause inflammation and skin thickening. The whole downstream cascade shuts down.
Why Targeting IL-23 Specifically Matters
Earlier biologics took a broader approach. Some blocked TNF-alpha, a general inflammation molecule involved in many immune functions. Others, like ustekinumab, blocked a protein subunit shared by both IL-12 and IL-23, which meant they affected two signaling pathways at once. IL-12 plays a role in fighting infections and possibly in tumor surveillance, so blocking it alongside IL-23 was a wider intervention than necessary.
Tremfya leaves IL-12 alone entirely. By targeting only the p19 subunit unique to IL-23, it narrows the suppression to just the part of the immune system driving disease. This selective approach is why IL-23 inhibitors as a class have become a preferred treatment for moderate-to-severe plaque psoriasis.
What Tremfya Is Approved to Treat
The FDA has approved Tremfya for four conditions: plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease. The underlying logic is similar across all four. Each condition involves IL-23-driven inflammation, though the location differs: skin in psoriasis, joints in psoriatic arthritis, and the digestive tract in ulcerative colitis and Crohn’s.
How Effective It Is in Practice
Clinical trial results for psoriasis have been strong. In the VOYAGE trials, about 70 to 73% of patients treated with Tremfya achieved a PASI 90 score (meaning 90% skin clearance) by week 16. For comparison, only about 2 to 3% of patients on placebo reached that level. By week 48, 76.3% of Tremfya patients had PASI 90 clearance, compared with 47.9% on adalimumab (Humira), a widely used TNF blocker.
Even among patients who had already failed on adalimumab and then switched to Tremfya, 66.1% achieved PASI 90 and 28.6% achieved complete clearance (PASI 100) by week 48. That’s notable because patients who don’t respond to one biologic often have a harder time responding to the next.
For psoriatic arthritis, the COSMOS trial showed that 44.4% of patients on Tremfya achieved at least a 20% improvement in joint symptoms (ACR20) at week 24, compared with 19.8% on placebo. Tremfya also outperformed placebo on physical function, quality of life, and skin clearance measures.
Dosing Schedule
For psoriasis and psoriatic arthritis, the schedule is straightforward: a 100 mg injection at the start, another at week 4, and then one every 8 weeks after that. All doses are self-injected under the skin.
For ulcerative colitis and Crohn’s disease, the process starts differently. The first three doses (at weeks 0, 4, and 8) are given by IV infusion at a clinic, each lasting at least one hour. After that induction phase, you transition to self-injected maintenance doses every 4 to 8 weeks depending on the dosing option your doctor selects. Crohn’s disease also offers a fully subcutaneous induction option at a higher dose.
How You Take It at Home
Tremfya comes in a single-dose device called a One-Press injector. You place it against your skin (typically the thigh or abdomen), push the handle down, and hold it in place while the medication injects. The speed is up to you. You may hear a click when the injection starts. When the handle can’t be pushed down any further and the teal-colored body of the device is no longer visible, the dose is complete. A needle guard locks automatically when you lift the device away.
One important detail: if you lift the injector before the dose is finished, the device locks and you won’t get the full amount. So the key instruction is to keep pressing until you can’t press any further.
How Quickly It Works
Most clinical data measures results at week 16, which is when the majority of psoriasis patients see substantial clearance. Some improvement typically begins earlier, but the 16-week mark is when the drug’s full effect becomes measurable. Results can continue to improve beyond that point. In trials, the percentage of patients reaching 90% skin clearance was slightly higher at week 48 than at week 16, suggesting that the benefit builds over time as the inflammatory cycle fully winds down.
Common Side Effects
Because Tremfya targets a narrow part of the immune system, its side effect profile is relatively mild. The most commonly reported reactions in trials were upper respiratory symptoms: sore throat, nasal congestion, cough, runny nose, and sneezing. Headache, body aches, fever, chills, and unusual tiredness were also reported. Stomach pain and injection-site reactions can occur. Serious infections are possible since the drug does partially suppress immune function, but the overall infection risk is lower than with broader-acting biologics.